Linno Pharmaceuticals

Shanghai-based rare disease specialist Linno Pharmaceuticals Inc. has reportedly raised close to RMB 100 million (USD 14.78 million) in angel and pre-Series A financing rounds. The round was led by Puhua Capital, with contributions from Zhangke Lingyi Investment. Funding UseProceeds will support upgrades in blood-brain barrier-crossing macromolecular drug delivery technology…